Study of tumor markers in terms of their importance in the grade and stage of stomach cancer.

Completed

Conditions: Malignant neoplasm of stomach, unspecified,

Registration Number: CTRI/2021/05/033905

Lead Sponsor: Chittaranjan National Cancer Institute

Brief Summary: Gastric adenocarcinoma was the predominant malignant gastric epithelial tumors with Tubular adenocarcinoma being the most frequent. Gastric carcinoma was more prevalent among males with a median age of 54 years and was significantly associated with a mixed diet pattern, smoking and a history of peptic disorder. The common presenting features were abdominal pain, weight loss, vomitting and anorexia. ERK1/2 expression was frequent in gastric carcinoma and showed a statistically significant association with gender, tumor size, Borrmann IV tumors, Diffuse type adenocarcinoma, signet ring and poorly cohesive carcinomas, higher tumor grade, higher T stage, higher N stage, presence of lymphovascular invasion and a higher AJCC prognostic stage. Bcl-2 expression was seen in a large proportion of gastric carcinomas and was significantly associated with gender, tumor size, Borrmann II tumors, Intestinal type adenocarcinomas, tubular and mucinous carcinomas, grade 2 tumors, higher T stage, higher N stage, presence of lymphovascular invasion and a higher AJCC prognostic stage. The association of Bcl-2 with the grade and stage of tumors was mostly seen in the Intestinal type adenocarcinomas. The study hypothesized a statistically significant association between ERK1/2 and Bcl-2 expression in gastric carcinomas, particularly in the Intestinal type, with a higher Bcl-2 expression in tumors having a high ERK1/2 expression. Diffuse type adenocarcinoma failed to show such an association. Higher expression of ERK1/2 and Bcl-2 in tumors having higher grade and higher stage indicated a probable prognostic values of these markers in gastric carcinomas.

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 63

Inclusion Criteria

Patients who will be operated for gastric neoplasm and will be diagnosed with malignant gastric epithelial neoplasms histopathologically.
Those who will give informed consent for taking part in the study.

Exclusion Criteria

After histopathological diagnosis all benign gastric neoplasms will be excluded.
After histopathological diagnosis gastric neoplasms other than malignant gastric epithelial neoplasms will be excluded.
Cases where Neoadjuvant chemotherapy have been administered.
Those who are not willing to take part in the study.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
2. To study the expression of biomarkers ERK1/2 and Bcl-2 in gastric carcinoma patients.	2 Years
1. To study the histopathological and clinicopathological parameters of Gastric Carcinoma in Eastern Indian population.	2 Years
3. To study the correlation between histopathological and clinicopathological parameters with ERK1/2 and Bcl-2 expression in gastric carcinoma patients.	2 Years

Secondary Outcome Measures

Name	Time	Method
To establish a correlation between ERK1/2 and Bcl-2 expression in gastric carcinoma if present.	2 Years

Trial Locations

Locations (1): Chittaranjan National Cancer Institute
🇮🇳
Kolkata, WEST BENGAL, India
Chittaranjan National Cancer Institute
🇮🇳Kolkata, WEST BENGAL, India
Raya Banerjee
Principal investigator
7003251081
guria2181994@gmail.com